Literature DB >> 30789754

Mechanisms of Niemann-Pick type C1 Like 1 protein degradation in intestinal epithelial cells.

Pooja Malhotra1, Vinay Soni1, Yoshihide Yamanashi2,3, Tappei Takada2,3, Hiroshi Suzuki2,3, Ravinder K Gill1, Seema Saksena4,1, Pradeep K Dudeja4,1, Waddah A Alrefai4,1.   

Abstract

Intestinal Niemann-Pick C1 Like 1 (NPC1L1) protein plays a key role in cholesterol absorption. A decrease in NPC1L1 expression has been implicated in lowering plasma cholesterol and mitigating the risk for coronary heart disease. Little is known about the mechanisms responsible for NPC1L1 protein degradation that upon activation may lead to a reduction in NPC1L1 protein levels in intestinal epithelial cells (IECs). In current studies, the human intestinal Caco-2 and HuTu-80 cell lines expressing NPC1L1-hemagglutinin fusion protein were used to investigate the mechanisms of NPC1L1 protein degradation. Incubation with the proteasome inhibitors MG-132 and lactacystin (10 μM, 24 h) significantly increased NPC1L1 protein levels in IECs. Also, the inhibition of the lysosomal pathway with bafilomycin A1 (80 nM, 24 h) resulted in a significant increase in NPC1L1 protein levels. Immunoprecipitation studies showed that NPC1L1 protein is both a poly- and monoubiquinated polypeptide and that the inhibition of the proteasomal pathway remarkably increased the level of the polyubiquinated NPC1L1. The surface expression of NPC1L1 was increased by the inhibition of both proteasomal and lysosomal pathways. Furthermore, the pharmacological inhibition of mitogen-activated protein kinase pathway (PD-98059, 15 μM, 24 h) and siRNA silencing of ERK1/2 resulted in a significant decrease in NPC1L1 protein levels in IECs. In conclusion, our results showed that basal level of intestinal cholesterol transporter NPC1L1 protein is modulated by both ubiquitin proteasome- and lysosome-dependent degradation as well as by ERK1/2-dependent pathway. The modulation of these pathways may provide novel clues for therapeutic intervention to inhibit cholesterol absorption and lower plasma cholesterol.

Entities:  

Keywords:  cholesterol absorption; lysosomal degradation; ubiquitin proteasome degradation

Mesh:

Substances:

Year:  2019        PMID: 30789754      PMCID: PMC6482670          DOI: 10.1152/ajpcell.00465.2018

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  25 in total

1.  Proteasomal inhibition promotes ATP-binding cassette transporter A1 (ABCA1) and ABCG1 expression and cholesterol efflux from macrophages in vitro and in vivo.

Authors:  Masatsune Ogura; Makoto Ayaori; Yoshio Terao; Tetsuya Hisada; Maki Iizuka; Shunichi Takiguchi; Harumi Uto-Kondo; Emi Yakushiji; Kazuhiro Nakaya; Makoto Sasaki; Tomohiro Komatsu; Hideki Ozasa; Fumitaka Ohsuzu; Katsunori Ikewaki
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-08-04       Impact factor: 8.311

Review 2.  Ubiquitin and the control of protein fate in the secretory and endocytic pathways.

Authors:  J S Bonifacino; A M Weissman
Journal:  Annu Rev Cell Dev Biol       Date:  1998       Impact factor: 13.827

3.  Lysine 63-linked polyubiquitination is required for EGF receptor degradation.

Authors:  Fangtian Huang; Xuemei Zeng; Woong Kim; Manimalha Balasubramani; Arola Fortian; Steven P Gygi; Nathan A Yates; Alexander Sorkin
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-09       Impact factor: 11.205

4.  N-glycosylation is essential for ileal ASBT function and protection against proteases.

Authors:  Saminathan Muthusamy; Pooja Malhotra; Mobashir Hosameddin; Amish K Dudeja; Sujata Borthakur; Seema Saksena; Ravinder K Gill; Pradeep K Dudeja; Waddah A Alrefai
Journal:  Am J Physiol Cell Physiol       Date:  2015-04-08       Impact factor: 4.249

5.  The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1).

Authors:  Margarita Garcia-Calvo; JeanMarie Lisnock; Herbert G Bull; Brian E Hawes; Duane A Burnett; Matthew P Braun; James H Crona; Harry R Davis; Dennis C Dean; Patricia A Detmers; Michael P Graziano; Meredith Hughes; D Euan Macintyre; Anthony Ogawa; Kim A O'neill; Sai Prasad N Iyer; Diane E Shevell; Marsha M Smith; Yui S Tang; Amanda M Makarewicz; Feroze Ujjainwalla; Scott W Altmann; Kevin T Chapman; Nancy A Thornberry
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-31       Impact factor: 11.205

6.  Epigenetic modulation of intestinal cholesterol transporter Niemann-Pick C1-like 1 (NPC1L1) gene expression by DNA methylation.

Authors:  Pooja Malhotra; Vinay Soni; Anoop Kumar; Arivarasu N Anbazhagan; Amish Dudeja; Seema Saksena; Ravinder K Gill; Pradeep K Dudeja; Waddah A Alrefai
Journal:  J Biol Chem       Date:  2014-06-05       Impact factor: 5.157

Review 7.  NPC1L1 and cholesterol transport.

Authors:  Jenna L Betters; Liqing Yu
Journal:  FEBS Lett       Date:  2010-03-19       Impact factor: 4.124

8.  HNF4alpha is a crucial modulator of the cholesterol-dependent regulation of NPC1L1.

Authors:  Yuki Iwayanagi; Tappei Takada; Hiroshi Suzuki
Journal:  Pharm Res       Date:  2007-12-14       Impact factor: 4.200

9.  K63 linked ubiquitin chain formation is a signal for HIF1A degradation by Chaperone-Mediated Autophagy.

Authors:  Joao Vasco Ferreira; Ana Rosa Soares; Jose Silva Ramalho; Paulo Pereira; Henrique Girao
Journal:  Sci Rep       Date:  2015-05-11       Impact factor: 4.379

10.  Inhibition of mitogen-activated protein kinase Erk1/2 promotes protein degradation of ATP binding cassette transporters A1 and G1 in CHO and HuH7 cells.

Authors:  Vishwaroop Mulay; Peta Wood; Melanie Manetsch; Masoud Darabi; Rose Cairns; Monira Hoque; Karen Cecilia Chan; Meritxell Reverter; Anna Alvarez-Guaita; Kerry-Anne Rye; Carles Rentero; Joerg Heeren; Carlos Enrich; Thomas Grewal
Journal:  PLoS One       Date:  2013-04-25       Impact factor: 3.240

View more
  2 in total

Review 1.  Eryngium Species as a Potential Ally for Treating Metabolic Syndrome and Diabetes.

Authors:  Eréndira Patricia Pérez-Muñoz; Marilena Antunes-Ricardo; Mariana Martínez-Ávila; Daniel Guajardo-Flores
Journal:  Front Nutr       Date:  2022-05-20

Review 2.  Role of Cholesterol and Lipid Rafts in Cancer Signaling: A Promising Therapeutic Opportunity?

Authors:  Rosa Vona; Elisabetta Iessi; Paola Matarrese
Journal:  Front Cell Dev Biol       Date:  2021-03-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.